Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Unicycive Therapeutics, Inc. (UNCY)
USD5.09
-0.13 (-2.49%)
US NASDAQ Healthcare Biotechnology
Address
4300 El Camino Real 94022
Los Altos, CA, US
Los Altos, CA, US
CEO
Shalabh K. Gupta
Website
unicycive.com
IPO
2021-07-12
CIK 1766140 ISIN US90466Y2028
Description
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
News Sentiment (7d)
7 articles
- Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation Business Wire
- UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc. GlobeNewsWire
- Unicycive Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses Newsfile Corp
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD5.09
-0.13 (-2.49%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.73
Float Shares
19.07M
Free Float %
88.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.77% | +0.62% | +23.23% | +34.38% | +58.95% | +41.59% | +44.35% | -40.80% | -83.66% | -83.66% | -83.66% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Buy
Price Targets & DCF
Current price
5.09
DCF (Unlevered)
0.18
-96.4%
DCF (Levered)
0.18
-96.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 8 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-0.35
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+70.2% ★ Q1'26: -7.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2,271.7% Q1'26: +1,830.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 8 EPS Ana. |
Dec 2027 6 Rev. Ana. 5 EPS Ana. |
Dec 2028 7 Rev. Ana. 6 EPS Ana. |
Dec 2029 3 Rev. Ana. 4 EPS Ana. |
Dec 2030 6 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
951.0K
est: 967.3K (-1.7%)
|
675.0K
est: 491.7K (+37.3%)
|
—
est: 10.00M (-100.0%)
|
—
est: 517.0K (-100.0%)
|
42.92M
2.54M – 147.59M
+8,200.8% YoY
|
382.51M
83.41M – 1.02B
+791.3% YoY
|
609.85M
583.56M – 636.15M
+59.4% YoY
|
563.00M
119.60M – 1.69B
-7.7% YoY
|
545.15M
115.80M – 1.63B
-3.2% YoY
|
| EBITDA |
-17.89M
est: 193.5K (-9,347.6%)
|
-30.18M
est: 98.3K (-30,789.6%)
|
-36.23M
est: 2.00M (-1,911.5%)
|
-25.91M
est: 103.4K (-25,160.2%)
|
8.58M
508.9K – 29.52M
+8,200.9% YoY
|
76.50M
16.68M – 204.44M
+791.3% YoY
|
121.97M
116.71M – 127.23M
+59.4% YoY
|
112.60M
23.92M – 337.62M
-7.7% YoY
|
109.03M
23.16M – 326.92M
-3.2% YoY
|
| EBIT |
-18.05M
est: 193.5K (-9,430.8%)
|
-30.46M
est: 98.3K (-31,078.4%)
|
-36.66M
est: 2.00M (-1,932.9%)
|
-26.48M
est: 103.4K (-25,713.4%)
|
8.58M
508.9K – 29.52M
+8,200.9% YoY
|
76.50M
16.68M – 204.44M
+791.3% YoY
|
121.97M
116.71M – 127.23M
+59.4% YoY
|
112.60M
23.92M – 337.62M
-7.7% YoY
|
109.03M
23.16M – 326.92M
-3.2% YoY
|
| Net Income |
-18.06M
est: -30.09M (+40.0%)
|
-30.54M
est: -24.41M (-25.1%)
|
-36.73M
est: -903.04M (+95.9%)
|
-26.56M
est: -227.86M (+88.3%)
|
-16.79M
-28.11B – 20.81B
+92.6% YoY
|
226.37M
146.91M – 3.24B
+1,448.4% YoY
|
1.89B
672.48M – 3.11B
+734.5% YoY
|
1.39B
-33.22M – 5.01B
-26.3% YoY
|
1.30B
-31.11M – 4.69B
-6.3% YoY
|
| SGA |
6.57M
est: 4.37M (+50.4%)
|
8.55M
est: 2.22M (+285.1%)
|
12.10M
est: 45.14M (-73.2%)
|
20.40M
est: 2.33M (+774.1%)
|
193.70M
11.48M – 666.13M
+8,200.8% YoY
|
1.73B
376.46M – 4.61B
+791.3% YoY
|
2.75B
2.63B – 2.87B
+59.4% YoY
|
2.54B
539.80M – 7.62B
-7.7% YoY
|
2.46B
522.68M – 7.38B
-3.2% YoY
|
| EPS |
-1.20
est: -11.03 (+89.1%)
|
-1.28
est: -11.08 (+88.4%)
|
-5.60
est: -5.14 (-8.9%)
|
-1.67
est: -1.43 (-16.4%)
|
-0.60
-176.91 – 130.97
+58.4% YoY
|
6.75
0.92 – 20.37
+1,230.8% YoY
|
10.18
4.23 – 19.55
+50.9% YoY
|
8.77
-0.21 – 31.55
-13.9% YoY
|
8.21
-0.20 – 29.54
-6.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-28.65M
OE per share TTM
-1.09
Owner's Yield
-1.47%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
135.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
14
Total invested
7.47M
Insider transactions (90d)
0
Beneficial owners (>5%)
27
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Opportunity Fund Holdings, L.P. | 59.96M | 9.99% | 59.96M | — | 59.96M | — | PN | Delaware | 2023-07-14 | ↗ |
| 2 | Opportunity, LLC | 59.96M | 9.99% | 59.96M | — | 59.96M | — | OO | Delaware | 2023-07-14 | ↗ |
| 3 | Dr. Jeffrey R. Jay, M.D. | 8.56M | 9.99% | — | 8.56M | — | — | HC, IN | USA | 2024-07-18 | ↗ |
| 4 | Great Point Partners, LLC | 8.56M | 9.99% | — | 8.56M | — | — | IA, OO | Delaware | 2024-07-18 | ↗ |
| 5 | Mr. Ortav Yehudai | 8.56M | 9.99% | — | 8.56M | — | — | HC, IN | USA | 2024-07-18 | ↗ |
| 6 | Octagon Capital Advisors LP | 8.56M | 9.10% | — | 8.56M | — | 8.56M | IA, PN | Delaware | 2024-10-11 | ↗ |
| 7 | Ting Jia | 8.56M | 9.10% | — | 8.56M | — | 8.56M | HC, IN | Delaware | 2024-10-11 | ↗ |
| 8 | Octagon Investments Master Fund LP | 5.56M | 5.90% | — | 5.56M | — | 5.56M | PN, OO | Delaware | 2024-10-11 | ↗ |
| 9 | Walleye Capital LLC | 5.00M | 5.30% | 5.00M | — | 5.00M | — | IA | Minnesota | 2024-11-13 | ↗ |
| 10 | Peter Kolchinsky | 3.47M | 9.99% | — | 3.47M | — | 3.47M | HC, IN | Delaware | 2023-07-06 | ↗ |
| 11 | RA Capital Healthcare Fund, L.P. | 3.47M | 9.99% | — | 3.47M | — | 3.47M | PN | Delaware | 2023-07-06 | ↗ |
| 12 | RA Capital Management, L.P. | 3.47M | 9.99% | — | 3.47M | — | 3.47M | IA, PN | Delaware | 2023-07-06 | ↗ |
| 13 | Rajeev Shah | 3.47M | 9.99% | — | 3.47M | — | 3.47M | HC, IN | Delaware | 2023-07-06 | ↗ |
| 14 | Arsani William | 3.47M | 11.00% | — | 3.47M | — | 3.47M | HC, IN | Delaware | 2024-01-22 | ↗ |
| 15 | Logos Global Management GP LLC | 3.47M | 11.00% | — | 3.47M | — | 3.47M | HC, OO | Delaware | 2024-01-22 | ↗ |
| 16 | Logos Global Management LP | 3.47M | 11.00% | — | 3.47M | — | 3.47M | IA, PN | Delaware | 2024-01-22 | ↗ |
| 17 | Logos Opportunities Fund III LP | 3.47M | 11.00% | — | 3.47M | — | 3.47M | PN | Delaware | 2024-01-22 | ↗ |
| 18 | Logos Opportunities II GP, LLC | 3.47M | 11.00% | — | 3.47M | — | 3.47M | OO | Delaware | 2024-01-22 | ↗ |
| 19 | Octagon Private Opportunities Fund II LP | 3.00M | 3.20% | — | 3.00M | — | 3.00M | PN, OO | Delaware | 2024-10-11 | ↗ |
| 20 | NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP | 2.12M | 6.10% | — | 2.12M | — | — | PN | MA | 2024-02-05 | ↗ |
| 21 | Biotechnology Value Fund, L.P. | 1.86M | 5.30% | — | 1.41M | — | 1.41M | PN | Delaware | 2023-07-06 | ↗ |
| 22 | Daniel Mack | 1.25M | 8.00% | — | 1.25M | — | — | HC | USA | 2022-02-14 | ↗ |
| 23 | Nantahala Capital Management, LLC | 1.25M | 8.00% | — | 1.25M | — | — | IA | MA | 2022-02-14 | ↗ |
| 24 | Wilmot B. Harkey | 1.25M | 8.00% | — | 1.25M | — | — | HC | USA | 2022-02-14 | ↗ |
| 25 | S | 812.6K | 5.60% | — | 812.6K | — | — | IN | ONTARIO, CANADA | 2021-09-23 | ↗ |
| 26 | Armistice Capital, LLC | 800.0K | 5.10% | — | 800.0K | — | 800.0K | IA, OO | — | 2022-02-15 | ↗ |
| 27 | Steven Boyd | 800.0K | 5.10% | — | 800.0K | — | 800.0K | HC, IN | — | 2022-02-15 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
14
-23 vs prev Q
New positions
7
Closed positions
28
Increased
7
Reduced
4
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VIVO CAPITAL, LLC | 1.79M +— (+0.0%) | 10.33M +2.5M (+32.3%) | 9.91% +0.000 pp | 0.67% +0.040 pp | USD4.62 +24.9% | 3 qtrs — |
| 2 | MILLENNIUM MANAGEMENT LLC | 1.01M +1.0M (+100.0%) | 5.86M +5.9M (+100.0%) | 5.62% +5.618 pp | 0.00% +0.003 pp | USD5.77 +0.0% | 1 qtrs NEW |
| 3 | OCTAGON CAPITAL ADVISORS LP | 1.00M +— (+0.0%) | 5.77M +1.4M (+32.3%) | 5.54% +0.000 pp | 0.70% +0.040 pp | USD4.77 +21.0% | 3 qtrs — |
| 4 | NANTAHALA CAPITAL MANAGEMENT, LLC | 939.2K +— (+0.0%) | 5.42M +1.3M (+32.3%) | 5.20% +0.000 pp | 0.18% +0.037 pp | USD4.77 +21.0% | 3 qtrs — |
| 5 | GREAT POINT PARTNERS LLC | 796.6K +— (+0.0%) | 4.60M +1.1M (+32.3%) | 4.41% +0.000 pp | 1.49% +0.058 pp | USD4.77 +21.0% | 3 qtrs — |
| 6 | VANGUARD GROUP INC | 788.6K +129.7K (+19.7%) | 4.55M +1.7M (+58.4%) | 4.37% +0.718 pp | 0.00% +0.000 pp | USD4.91 +17.5% | 3 qtrs — |
| 7 | LOGOS GLOBAL MANAGEMENT LP | 473.6K +— (+0.0%) | 2.73M +667.7K (+32.3%) | 2.62% +0.000 pp | 0.17% -0.020 pp | USD4.77 +21.0% | 3 qtrs — |
| 8 | CITADEL ADVISORS LLC | 258.3K +216.6K (+519.8%) | 1.49M +1.3M (+720.3%) | 1.43% +1.199 pp | 0.00% +0.000 pp | USD5.54 +4.2% | 2 qtrs — |
| 9 | CANTOR FITZGERALD, L. P. | 200.0K +200.0K (+100.0%) | 1.15M +1.2M (+100.0%) | 1.11% +1.107 pp | 0.02% +0.018 pp | USD5.77 +0.0% | 1 qtrs NEW |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 171.3K +45.6K (+36.2%) | 989.2K +441.0K (+80.5%) | 0.95% +0.252 pp | 0.00% +0.000 pp | USD4.88 +18.2% | 3 qtrs — |
| 11 | BNP PARIBAS ARBITRAGE, SNC | 99.7K +99.7K (+181,249.1%) | 575.5K +575.3K (+239,696.3%) | 0.55% +0.552 pp | 0.00% +0.000 pp | USD5.77 +0.0% | 2 qtrs — |
| 12 | DAUNTLESS INVESTMENT GROUP, LLC | 89.4K +89.4K (+100.0%) | 515.9K +515.9K (+100.0%) | 0.50% +0.495 pp | 0.41% +0.410 pp | USD5.77 +0.0% | 1 qtrs NEW |
| 13 | OMERS ADMINISTRATION CORP | 78.2K +78.2K (+100.0%) | 451.2K +451.2K (+100.0%) | 0.43% +0.433 pp | 0.00% +0.003 pp | USD5.77 +0.0% | 1 qtrs NEW |
| 14 | STATE STREET CORP | 65.2K +10.4K (+19.0%) | 376.4K +137.3K (+57.4%) | 0.36% +0.058 pp | 0.00% +0.000 pp | USD4.66 +23.8% | 3 qtrs — |
| 15 | ACUTA CAPITAL PARTNERS, LLC | 60.0K +— (+0.0%) | 346.1K +84.6K (+32.3%) | 0.33% +0.000 pp | 0.24% -0.035 pp | USD4.77 +21.0% | 3 qtrs — |
| 16 | SQUAREPOINT OPS LLC | 55.3K -62.0K (-52.9%) | 319.1K -192.4K (-37.6%) | 0.31% -0.343 pp | 0.00% 0.000 pp | USD4.36 +32.3% | 2 qtrs — |
| 17 | MORGAN STANLEY | 46.6K +36.0K (+339.0%) | 268.8K +222.5K (+480.9%) | 0.26% +0.199 pp | 0.00% +0.000 pp | USD5.46 +5.7% | 3 qtrs — |
| 18 | QUADRATURE CAPITAL LTD | 39.1K +39.1K (+100.0%) | 225.7K +225.7K (+100.0%) | 0.22% +0.217 pp | 0.00% +0.002 pp | USD5.77 +0.0% | 1 qtrs NEW |
| 19 | BLACKROCK, INC. | 36.4K +— (+0.0%) | 209.8K +51.3K (+32.3%) | 0.20% +0.000 pp | 0.00% +0.000 pp | USD4.36 +32.3% | 2 qtrs — |
| 20 | NORTHERN TRUST CORP | 35.9K +3.2K (+9.9%) | 207.4K +64.8K (+45.4%) | 0.20% +0.018 pp | 0.00% +0.000 pp | USD4.61 +25.2% | 3 qtrs — |
| 21 | XTX TOPCO LTD | 35.4K -2.4K (-6.4%) | 204.3K +39.4K (+23.9%) | 0.20% -0.013 pp | 0.01% -0.003 pp | USD4.36 +32.3% | 2 qtrs — |
| 22 | CHICAGO PARTNERS INVESTMENT GROUP LLC | 22.4K -4.5K (-16.9%) | 155.1K +27.8K (+21.9%) | 0.12% -0.025 pp | 0.00% +0.001 pp | USD4.36 +32.3% | 2 qtrs — |
| 23 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 24.9K +24.9K (+100.0%) | 143.9K +143.9K (+100.0%) | 0.14% +0.138 pp | 0.00% +0.000 pp | USD5.77 +0.0% | 1 qtrs NEW |
| 24 | JANE STREET GROUP, LLC | 20.9K +20.9K (+100.0%) | 120.6K +120.6K (+100.0%) | 0.12% +0.116 pp | 0.00% +0.000 pp | USD5.77 +0.0% | 1 qtrs NEW |
| 25 | UBS GROUP AG | 19.9K +14.5K (+265.6%) | 114.9K +91.1K (+383.8%) | 0.11% +0.080 pp | 0.00% +0.000 pp | USD5.38 +7.2% | 2 qtrs — |
| 26 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.9K +1.9K (+100.0%) | 11.1K +11.1K (+100.0%) | 0.01% +0.011 pp | 0.00% +0.000 pp | USD5.77 +0.0% | 1 qtrs NEW |
| 27 | SBI SECURITIES CO., LTD. | 558.00 -2.0 (-0.4%) | 3.2K +778.0 (+31.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.76 +21.2% | 3 qtrs — |
| 28 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 500.00 +— (+0.0%) | 2.9K +705.0 (+32.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.36 +32.3% | 2 qtrs — |
| 29 | TFC FINANCIAL MANAGEMENT, INC. | 300.00 +— (+0.0%) | 1.7K +423.0 (+32.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.36 +32.3% | 2 qtrs — |
| 30 | CITIGROUP INC | 228.00 -6.5K (-96.6%) | 1.3K -27.9K (-95.5%) | 0.00% -0.036 pp | 0.00% +0.000 pp | USD4.36 +32.3% | 2 qtrs — |
| 31 | BANK OF AMERICA CORP /DE/ | 152.00 -675.0 (-81.6%) | 877.00 -2.7K (-75.7%) | 0.00% -0.004 pp | 0.00% +0.000 pp | USD4.39 +31.4% | 3 qtrs — |
| 32 | HARBOUR INVESTMENTS, INC. | 100.00 +— (+0.0%) | 577.00 +141.0 (+32.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.76 +21.2% | 3 qtrs — |
| 33 | BARCLAYS PLC | 80.00 +— (+0.0%) | 462.00 +113.0 (+32.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.76 +21.2% | 3 qtrs — |
| 34 | BOGART WEALTH, LLC | 6.00 +— (+0.0%) | 35.00 +9.0 (+34.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.67 +23.6% | 3 qtrs — |
| 35 | DANSKE BANK A/S | 1.00 +— (+0.0%) | 6.00 +2.0 (+50.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.00 +44.3% | 3 qtrs — |
| 36 | FORTITUDE FAMILY OFFICE, LLC | — -107.0 (-100.0%) | — -467.0 (-100.0%) | 0.00% -0.001 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 37 | GOLDMAN SACHS GROUP INC | — -45.2K (-100.0%) | — -197.1K (-100.0%) | 0.00% -0.250 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 41 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.03% | 427.1K | 0.60% |
| 2 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.01% | 136.2K | 0.20% |
| 3 | iShares Russell 2000 Growth ETF IWO | 0.01% | 1.05M | 0.24% |
| 4 | State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc) R2US.L | 0.01% | 333.5K | 0.30% |
| 5 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 170.7K | 0.30% |
| 6 | Global X - Russell 2000 ETF RSSL | 0.00% | 59.5K | 0.08% |
| 7 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.00% | 12.9K | 0.25% |
| 8 | iShares Russell 2000 BuyWrite ETF IWMW | 0.00% | 2.2K | 0.39% |
| 9 | iShares Russell 2000 ETF IWM | 0.00% | 3.27M | 0.19% |
| 10 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.00% | 21.4K | 0.36% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
8.00
Bullish
Ratio by volume
3.00
Bullish
Buys
8
Sells
1
Shares acquired
1.15M
Shares disposed
3.2K
Cash buys
—
Cash sales
—
Net activity
+1,148,301
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-25 | Aggarwal Gaurav | Director | C-Conversion | A | Common Stock | 652,900 | 0.00 | — | 1,789,915 | I | ↗ |
| 2025-07-28 | Townsend John | Officer | A-Award | A | Stock Options | 10,000 | 4.71 | 47.1K | 101,557 | D | ↗ |
| 2025-07-28 | Laumas Sandeep | Director | A-Award | A | Stock Options | 21,200 | 4.71 | 99.9K | 41,286 | D | ↗ |
| 2025-07-28 | Kenkare-Mitra Sara | Director | A-Award | A | Stock Options | 21,200 | 4.71 | 99.9K | 39,200 | D | ↗ |
| 2025-07-28 | Jermasek Douglas | Officer | A-Award | A | Stock Options | 10,000 | 4.71 | 47.1K | 215,500 | D | ↗ |
| 2025-07-28 | Gupta Shalabh K. | Director / Officer | A-Award | A | Stock Options | 325,000 | 4.71 | 1.53M | 968,951 | D | ↗ |
| 2025-07-28 | Gupta Pramod | Officer | A-Award | A | Stock Options | 90,000 | 4.71 | 423.9K | 301,986 | D | ↗ |
| 2025-07-28 | Aggarwal Gaurav | Director | A-Award | A | Stock Options | 21,200 | 4.71 | 99.9K | 39,200 | D | ↗ |
| 2025-02-18 | Aggarwal Gaurav | Director | C-Conversion | A | Common Stock | 1,400,000 | 0.00 | — | 11,370,152 | I | ↗ |
| 2024-10-09 | Aggarwal Gaurav | Director | C-Conversion | A | Common Stock | 5,500,000 | 1,000.00 | 5.50B | 9,970,152 | I | ↗ |
| 2024-08-12 | Townsend John | Officer | A-Award | A | Stock Options | 40,256 | 0.34 | 13.7K | 915,565 | — | ↗ |
| 2024-08-12 | Jermasek Douglas | Officer | A-Award | A | Stock Options | 81,750 | 0.34 | 27.8K | 2,055,000 | — | ↗ |
| 2024-08-12 | Gupta Shalabh K. | Director / Officer | A-Award | A | Stock Options | 232,868 | 0.34 | 79.2K | 6,439,505 | — | ↗ |
| 2024-08-12 | Gupta Pramod | Officer | A-Award | A | Stock Options | 81,750 | 0.34 | 27.8K | 2,119,862 | — | ↗ |
| 2024-04-15 | Townsend John | Officer | A-Award | A | Stock Options | 228,119 | 1.14 | 260.1K | 875,309 | — | ↗ |
| 2024-04-15 | Jermasek Douglas | Officer | A-Award | A | Stock Options | 463,250 | 1.14 | 528.1K | 1,973,250 | — | ↗ |
| 2024-04-15 | Gupta Shalabh K. | Director / Officer / 10% Owner | A-Award | A | Stock Options | 1,319,583 | 1.14 | 1.50M | 6,206,637 | — | ↗ |
| 2024-04-15 | Gupta Pramod | Officer | A-Award | A | Stock Options | 463,250 | 1.14 | 528.1K | 2,038,112 | — | ↗ |
| 2023-09-05 | Ryan John L | Director | A-Award | A | Stock Options | 112,147 | 0.76 | 85.2K | 123,775 | — | ↗ |
| 2023-09-05 | Laumas Sandeep | Director | A-Award | A | Stock Options | 189,236 | 0.76 | 143.8K | 200,864 | — | ↗ |
| 2023-09-05 | Kenkare-Mitra Sara | Director | A-Award | A | Stock Options | 180,000 | 0.76 | 136.8K | 180,000 | — | ↗ |
| 2023-09-05 | Aggarwal Gaurav | Director | A-Award | A | Stock Options | 180,000 | 0.76 | 136.8K | 180,000 | — | ↗ |
| 2023-08-28 | Townsend John | Officer | A-Award | A | Stock Options | 570,329 | 0.75 | 427.7K | 647,190 | — | ↗ |
| 2023-08-28 | Jermasek Douglas | Officer | A-Award | A | Stock Options | 1,355,000 | 0.75 | 1.02M | 1,510,000 | — | ↗ |
| 2023-08-28 | Gupta Shalabh K. | Director / Officer | A-Award | A | Stock Options | 4,684,775 | 0.75 | 3.51M | 4,988,798 | — | ↗ |
| 2023-08-28 | Gupta Pramod | Officer | A-Award | A | Stock Options | 1,355,000 | 0.75 | 1.02M | 1,574,862 | — | ↗ |
| 2023-07-11 | Jermasek Douglas | Officer | M-Exempt | A | Warrant (right to buy) | 115,275 | 0.74 | 85.3K | 115,275 | — | ↗ |
| 2023-07-11 | Gupta Shalabh K. | Director / Officer | M-Exempt | A | Warrant (right to buy | 79,252 | 0.54 | 42.8K | 79,252 | — | ↗ |
| 2023-07-11 | Gupta Pramod | Officer | M-Exempt | A | Common Stock | 41,845 | 0.49 | 20.5K | 41,845 | — | ↗ |
| 2023-07-11 | Aggarwal Gaurav | Director | C-Conversion | A | Common Stock | 3,470,152 | 0.00 | — | 3,470,152 | — | ↗ |
| 2023-03-08 | Jermasek Douglas | Officer | A-Award | A | Series A Convertible Preferred Stock | 50 | 0.49 | 24.67 | 50 | — | ↗ |
| 2023-03-08 | Gupta Shalabh K. | Director / Officer | A-Award | A | Series A Convertible Preferred Stock | 50 | 0.49 | 24.67 | 50 | — | ↗ |
| 2023-03-08 | Gupta Pramod | Officer | A-Award | A | Series A Convertible Preferred Stock | 20 | 0.49 | 9.87 | 20 | — | ↗ |
| 2023-03-08 | Aggarwal Gaurav | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-11-21 | Townsend John | Officer | A-Award | A | Stock Options | 35,000 | 0.00 | — | 76,861 | — | ↗ |
| 2022-11-21 | Jermasek Douglas | Officer | A-Award | A | Stock Options | 55,000 | 0.00 | — | 155,000 | — | ↗ |
| 2022-11-21 | Gupta Shalabh K. | Officer | A-Award | A | Stock Options | 86,000 | 0.00 | — | 202,279 | — | ↗ |
| 2022-11-21 | Gupta Pramod | Officer | A-Award | A | Stock Options | 28,000 | 0.00 | — | 219,862 | — | ↗ |
| 2022-11-18 | Jermasek Douglas | Director | — | D | Stock Options | 100,000 | 2.56 | 256.0K | — | — | ↗ |
| 2022-07-15 | Schiller Brigitte | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-05-16 | Schiller Brigitte | Director | P-Purchase | A | Common Stock | 15,000 | 0.83 | 12.4K | 15,000 | — | ↗ |
| 2021-07-15 | Townsend John | Officer | A-Award | A | Stock Options | 18,605 | 5.00 | 93.0K | 41,861 | — | ↗ |
| 2021-07-15 | Gupta Shalabh K. | Director / Officer | A-Award | A | Stock Options | 116,279 | 5.00 | 581.4K | 218,023 | — | ↗ |
| 2021-07-15 | Gupta Pramod | Officer | A-Award | A | Stock Options | 34,884 | 5.00 | 174.4K | 191,862 | — | ↗ |
| 2021-07-12 | Townsend John | Officer | — | D | Employee Stock Option (right to buy) | 23,256 | 7.01 | 163.0K | 0 | — | ↗ |
| 2021-07-12 | Schiller Brigitte | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-12 | Ryan John L | Director | — | D | Employee Stock Option (right to buy) | 11,628 | 0.01 | 116.28 | 0 | — | ↗ |
| 2021-07-12 | Laumas Sandeep | Director | — | D | Employee Stock Option (right to buy) | 11,628 | 0.01 | 116.28 | 0 | — | ↗ |
| 2021-07-12 | Gupta Shalabh K. | Director / Officer | — | D | Employee Stock Option (right to buy) | 101,744 | 0.01 | 1.0K | 0 | — | ↗ |
| 2021-07-12 | Gupta Pramod | Officer | — | D | Employee Stock Option (right to buy) | 58,140 | 3.27 | 190.1K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
21.49M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Shalabh Gupta, M.D., Chief Executive Officer | 572.0K | 486.2K | — | 1.33M | — | — | 2.39M | 55.75% | ↗ |
| 2 | 2025 | Pramod Gupta, Ph.D., Executive VP Pharmaceutical and Business Operations | 468.0K | 198.9K | — | 369.3K | — | — | 1.04M | 35.64% | ↗ |
| 3 | 2025 | Doug Jermasek, Executive VP, Corporate Strategy | 363.0K | 77.1K | — | 41.0K | — | — | 481.2K | 8.53% | ↗ |
| 4 | 2024 | Shalabh Gupta, M.D., Chief Executive Officer | 572.0K | 543.4K | — | 1.32M | — | — | 2.44M | 54.28% | ↗ |
| 5 | 2024 | Shalabh Gupta, M.D., Chief Executive Officer | 572.0K | 543.4K | — | 1.32M | — | — | 2.44M | 54.28% | ↗ |
| 6 | 2024 | Pramod Gupta, Ph.D., Executive VP Pharmaceutical and Business Operations | 468.0K | 222.3K | — | 465.0K | — | — | 1.16M | 40.25% | ↗ |
| 7 | 2024 | Pramod Gupta, Ph.D., Executive VP Pharmaceutical and Business Operations | 468.0K | 222.3K | — | 465.0K | — | — | 1.16M | 40.25% | ↗ |
| 8 | 2024 | Doug Jermasek, Executive VP, Corporate Strategy | 363.0K | 45.4K | — | 465.0K | — | — | 873.3K | 53.24% | ↗ |
| 9 | 2024 | Doug Jermasek, Executive VP, Corporate Strategy | 363.0K | 45.4K | — | 465.0K | — | — | 873.3K | 53.24% | ↗ |
| 10 | 2023 | Shalabh Gupta, M.D., Chief Executive Officer | 550.0K | 550.0K | — | 2.97M | — | — | 4.04M | 73.48% | ↗ |
| 11 | 2023 | Pramod Gupta, Ph.D., Executive VP Pharmaceutical and Business Operations | 450.0K | 225.0K | — | 859.5K | — | — | 1.52M | 56.42% | ↗ |
| 12 | 2023 | Doug Jermasek, Executive VP, Corporate Strategy | 330.0K | 82.5K | — | 859.5K | — | — | 1.27M | 67.79% | ↗ |
| 13 | 2022 | Shalabh Gupta, M.D., Chief Executive Officer | 550.0K | 908.0K | — | 53.7K | — | — | 1.51M | 3.55% | ↗ |
| 14 | 2022 | Pramod Gupta, Ph.D., Executive VP Pharmaceutical and Business Operations | 450.0K | 329.2K | — | 17.5K | — | — | 796.7K | 2.20% | ↗ |
| 15 | 2022 | Doug Jermasek, Executive VP, Corporate Strategy | 330.0K | 100.8K | — | 34.4K | — | — | 465.2K | 7.39% | ↗ |
| 16 | 2021 | Shalabh Gupta, M.D., Chief Executive Officer | 669.8K | 124.2K | — | 330.7K | — | — | 1.12M | 29.41% | ↗ |
| 17 | 2021 | Pramod Gupta, Ph.D., Executive VP Pharmaceutical and Business Operations | 187.5K | — | — | 231.6K | — | 68.8K | 487.8K | 47.47% | ↗ |
| 18 | 2021 | John Townsend, CPA, Chief Financial Officer | 91.7K | — | — | 185.3K | — | 106.2K | 383.1K | 48.35% | ↗ |
| 19 | 2020 | Shalabh Gupta, M.D., Chief Executive Officer | 495.0K | 148.5K | — | — | — | — | 643.5K | 0.00% | ↗ |
| 20 | 2020 | Pramod Gupta, Ph.D., Executive VP Pharmaceutical and | — | — | — | 212.3K | — | 60.0K | 272.3K | 77.96% | ↗ |
| 21 | 2020 | John Townsend, CPA, Chief Financial Officer | — | — | — | — | — | 39.8K | 39.8K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Shalabh K. Gupta | Founder, Chairman, Chief Executive Officer & President | 1M | — |
| Pramod Gupta | Executive Vice President of Pharmaceutical and Business Operations | 666.9K | — |
| Douglas Jermasek | Executive Vice President of Corporate Strategy | 440.1K | male |
| John W. Townsend | Chief Financial Officer | 197.9K | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for UNCY
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
